Braveheart Bio (NASDAQ:BRVE) Trading Down 5.2% – Time to Sell?

Braveheart Bio, Inc. (NASDAQ:BRVE)’s stock price dropped 5.2% during mid-day trading on Monday . The stock traded as low as $25.94 and last traded at $26.02. Approximately 150,202 shares changed hands during trading, a decline of 53% from the average session volume of 318,614 shares. The stock had previously closed at $27.44.

Braveheart Bio News Roundup

Here are the key news stories impacting Braveheart Bio this week:

• Positive Sentiment: New bullish analyst coverage: Goldman Sachs and Jefferies each initiated coverage with a Buy rating and a $48 price target, implying substantial upside. Stifel also assigned a Buy rating with a $45 target, while Cantor Fitzgerald rated the shares Overweight with a $40 target. The concentration of bullish coverage may be supporting investor interest in BRVE.
• Positive Sentiment: Insider buying highlights confidence: A report identified Braveheart Bio among healthcare companies whose insiders are buying shares, potentially signaling management confidence in the company’s valuation and pipeline prospects. Insiders Are Betting Big on These 3 Healthcare Stocks
• Neutral Sentiment: Upcoming investor presentation: Braveheart Bio will participate in the Cantor Global Healthcare Conference in New York from September 9-11. The event could provide investors with updates on its next-generation hypertrophic cardiomyopathy and cardiovascular disease programs, although no new data or guidance was announced. Braveheart Bio to Participate in Cantor Global Healthcare Conference
• Negative Sentiment: Recent one-year low remains a risk: Braveheart Bio recently reached a new 52-week low, underscoring continued volatility and concerns about the clinical-stage company despite the favorable analyst outlook. Braveheart Bio Reaches New 1-Year Low

Wall Street Analyst Weigh In

BRVE has been the topic of a number of recent research reports. Cantor Fitzgerald began coverage on Braveheart Bio in a research note on Monday. They set an “overweight” rating and a $40.00 price target on the stock. TD Cowen initiated coverage on Braveheart Bio in a research note on Monday. They issued a “buy” rating for the company. Wall Street Zen upgraded shares of Braveheart Bio to a “hold” rating in a report on Saturday, August 15th. The Goldman Sachs Group started coverage on shares of Braveheart Bio in a research report on Monday. They set a “buy” rating and a $48.00 target price on the stock. Finally, Stifel Nicolaus started coverage on shares of Braveheart Bio in a report on Monday. They set a “buy” rating and a $45.00 target price on the stock. Five equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $45.25.

Braveheart Bio Trading Up 3.1%

Insider Buying and Selling

In related news, major shareholder Growth Opportunities F. Forbion purchased 1,680,000 shares of the firm’s stock in a transaction dated Friday, August 7th. The stock was bought at an average price of $18.00 per share, with a total value of $30,240,000.00. Following the completion of the purchase, the insider owned 10,185,478 shares in the company, valued at approximately $183,338,604. This represents a 19.75% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, Director David Charles Lubner acquired 55,555 shares of the stock in a transaction dated Friday, August 7th. The shares were bought at an average price of $18.00 per share, with a total value of $999,990.00. Following the completion of the transaction, the director directly owned 55,555 shares of the company’s stock, valued at $999,990. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders have acquired 8,751,942 shares of company stock valued at $157,534,956.

About Braveheart Bio

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.